Owkin
Owkin Inks Deal to Offer Its Colorectal Cancer Test Through Proscia's Platform
The firms said that Owkin's MSIntuit CRC v2 screening test for microsatellite instability will be available through the Proscia Concentriq software platform.
Owkin Expands Into Western Europe With Nine Precision Medicine Partnerships
The firm will employ its machine learning-enabled diagnostic and drug discovery tools in nine centers across Germany, Austria, and Switzerland.
The firm has early results from more than 400 cancer samples suggesting the multimodal profiles could aid clinical decision-making and drug target discovery.
Owkin, MSD Collaborate on Digital Pathology Cancer Diagnostics
Owkin and MSD — known as Merck in the US and Canada — will develop and commercialize microsatellite instability high diagnostics in the EU for four types of cancer.
With $50M Investment in MOSAIC Project, Owkin Seeks to Become Cancer 'Drug Discovery Enterprise'
Premium
The MOSAIC research coalition brings together Owkin, NanoString, and European and US institutions to create a massive spatial omics dataset in pursuit of novel cancer biomarkers